Cover ImageSALE
市場調查報告書

癲癇:流行病學的預測

Epilepsy - Epidemiology Forecast to 2027

出版商 DelveInsight Business Research LLP 商品編碼 565332
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癲癇:流行病學的預測 Epilepsy - Epidemiology Forecast to 2027
出版日期: 2018年03月01日 內容資訊: 英文 50 Pages
簡介

本報告提供全球癲癇的流行病學的預測相關分析,在疾病概要和目前治療手法/演算法,全球整體及主要國家 (美國·歐洲各國·日本) 的患病人數趨勢預測 (總計12年份),各子類型詳細趨勢,今後的市場機會·醫藥品開發預測等相關調查。

第1章 簡介

第2章 疾病的背景情況

  • 簡介
  • 病因
  • 症狀
  • 分類
  • 風險要素
  • 診斷方法
  • 癲癇和結節性硬化症 (TSC) 突然變異
  • 目前治療方法與臨床診療

第3章 流行病學和患者人口

  • 分析的要點
  • 美國
    • 癲癇的患病人數
    • 男女的患病人數
    • 各子類型的患病人數
    • TSC (結節性硬化症) 伴隨的癲癇患病人數
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第4章 附錄

  • 分析方法

第5章 諮詢服務

第6章 免責聲明

第7章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIEI0283

DelveInsight's 'Epilepsy - Epidemiology Forecast to 2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Epilepsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Epilepsy Epidemiology:

The Epilepsy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Epilepsy are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

According to DelveInsight, the prevalent cases of Epilepsy was 7,649,695 in 2016 in 7 MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of Epilepsy with 4,007,026 prevalent cases in 2016 followed by Germany.

Epilepsy Epidemiology Segmentation:

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by sex-specific [Male and Female] and sub-type [Focal/ Partial, Generalized, Unclassified]. The report further covers prevalence of Tuberous Sclerosis Complex (TSC) associated Epilepsy.

Report Scope:

  • The report covers detailed overview of Epilepsy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of Epilepsy
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by gender and sub-types in 7MM

Key strengths:

  • 10 Year Forecast of Epilepsy epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Epilepsy
  • Prevalent Cases according to segmentation: Gender-specific prevalence, sub-type specific prevalence and prevalence of Tuberous Sclerosis Complex (TSC) associated Epilepsy

Key assessments:

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Report Summary

2. Epilepsy Disease Background

  • 2.1. Introduction
  • 2.2. Causes
  • 2.3. Symptoms
  • 2.4. Classification
  • 2.5. Risk factors
  • 2.6. Diagnosis
  • 2.7. TSC Mutations in Epilepsy
  • 2.8. Current Treatment & Medical Practices

3. Epidemiology and Patient Population

  • 3.1. Key Points
  • 3.2. United States
    • 3.2.1. Prevalence of Epilepsy in United States
    • 3.2.2. Gender specific prevalence in United States
    • 3.2.3. Sub-type specific prevalence in United States
    • 3.2.4. Prevalence of TSC associated Epilepsy in the United States
  • 3.3. Germany
    • 3.3.1. Prevalence of Epilepsy in Germany
    • 3.3.2. Gender specific prevalence in Germany
    • 3.3.3. Sub-type specific prevalence in Germany
    • 3.3.4. Prevalence of TSC associated Epilepsy in the Germany
  • 3.4. France
    • 3.4.1. Prevalence of Epilepsy in France
    • 3.4.2. Gender specific prevalence in France
    • 3.4.3. Sub-type specific prevalence in France
    • 3.4.4. Prevalence of TSC associated Epilepsy in the France
  • 3.5. Italy
    • 3.5.1. Prevalence of Epilepsy in Italy
    • 3.5.2. Gender specific prevalence in Italy
    • 3.5.3. Sub-type specific prevalence in Italy
    • 3.5.4. Prevalence of TSC associated Epilepsy in the Italy
  • 3.6. Spain
    • 3.6.1. Prevalence of Epilepsy in Spain
    • 3.6.2. Gender specific prevalence in Spain
    • 3.6.3. Sub-type specific prevalence in Spain
    • 3.6.4. Prevalence of TSC associated Epilepsy in the Spain
  • 3.7. United Kingdom
    • 3.7.1. Prevalence of Epilepsy in United Kingdom
    • 3.7.2. Gender specific prevalence in United Kingdom
    • 3.7.3. Sub-type specific prevalence in United Kingdom
    • 3.7.4. Prevalence of TSC associated Epilepsy in the UK
  • 3.8. Japan
    • 3.8.1. Prevalence of Epilepsy in Japan
    • 3.8.2. Gender specific prevalence in Japan
    • 3.8.3. Sub-type specific prevalence in Japan

4. Appendix

  • 4.1. Report Methodology

5. Consulting Services

6. Disclaimer

7. About DelveInsight

List of Tables

  • Table 1: Prevalent Population of Epilepsy in the United States (2016-2027)
  • Table 2: Gender specific Prevalent Population of Epilepsy in the United States (2016-2027)
  • Table 3: Sub-type specific Prevalent Population of Epilepsy in the United States (2016-2027)
  • Table 4: Prevalence of TSC associated Epilepsy in the United States (2016-2027)
  • Table 5: Prevalent Population of Epilepsy in the Germany (2016-2027)
  • Table 6: Gender specific Prevalent Population of Epilepsy in the Germany (2016-2027)
  • Table 7: Sub-type specific Prevalent Population of Epilepsy in the United States (2016-2027)
  • Table 8: Prevalence of TSC associated Epilepsy in the Germany (2016-2027)
  • Table 9: Prevalent Population of Epilepsy in the France (2016-2027)
  • Table 10: Gender specific Prevalent Population of Epilepsy in the France (2016-2027)
  • Table 11: Sub-type specific Prevalent Population of Epilepsy in the France (2016-2027)
  • Table 12: Prevalence of TSC associated Epilepsy in the France (2016-2027)
  • Table 13: Prevalent Population of Epilepsy in the Italy (2016-2027)
  • Table 14: Gender specific Prevalent Population of Epilepsy in the Italy (2016-2027)
  • Table 15: Sub-type specific Prevalent Population of Epilepsy in the Italy (2016-2027)
  • Table 16: Prevalence of TSC associated Epilepsy in the Italy (2016-2027)
  • Table 17: Prevalent Population of Epilepsy in the Spain (2016-2027)
  • Table 18: Gender specific Prevalent Population of Epilepsy in the Spain (2016-2027)
  • Table 19: Sub-type specific Prevalent Population of Epilepsy in the Spain (2016-2027)
  • Table 20: Prevalence of TSC associated Epilepsy in the Spain (2016-2027)
  • Table 21: Prevalent Population of Epilepsy in the United Kingdom (2016-2027)
  • Table 22: Gender specific Prevalent Population of Epilepsy in the UK (2016-2027)
  • Table 23: Sub-type specific Prevalent Population of Epilepsy in the UK (2016-2027)
  • Table 24: Prevalence of TSC associated Epilepsy in the UK (2016-2027)
  • Table 25: Prevalent Population of Epilepsy in the Japan (2016-2027)
  • Table 26: Gender specific Prevalent Population of Epilepsy in the Japan (2016-2027)
  • Table 27: Sub-type specific Prevalent Population of Epilepsy in the Japan (2016-2027)

List of Figures

  • Figure 1: ILAE 2017 Classification of Seizure Types Basic Version
  • Figure 2: ILAE 2017 Classification of Seizure Types Extended Version
  • Figure 3: Classification of Epilepsy
  • Figure 4: Prevalent Population of Epilepsy in the United States (2016-2027)
  • Figure 5: Gender specific Prevalent Population of Epilepsy in the United States (2016-2027)
  • Figure 6: Sub-type specific Prevalent Population of Epilepsy in the United States (2016-2027)
  • Figure 7: Prevalence of TSC associated Epilepsy in the United States (2016-2027)
  • Figure 8: Prevalent Population of Epilepsy in the Germany (2016-2027)
  • Figure 9: Gender specific Prevalent Population of Epilepsy in the Germany (2016-2027)
  • Figure 10: Sub-type specific Prevalent Population of Epilepsy in the Germany (2016-2027)
  • Figure 11: Prevalence of TSC associated Epilepsy in the Germany (2016-2027)
  • Figure 12: Prevalent Population of Epilepsy in the France (2016-2027)
  • Figure 13: Gender specific Prevalent Population of Epilepsy in the France (2016-2027)
  • Figure 14: Sub-type specific Prevalent Population of Epilepsy in the France (2016-2027)
  • Figure 15: Prevalence of TSC associated Epilepsy in the France (2016-2027)
  • Figure 16: Prevalent Population of Epilepsy in the Italy (2016-2027)
  • Figure 17: Gender specific Prevalent Population of Epilepsy in the Italy (2016-2027)
  • Figure 18: Sub-type specific Prevalent Population of Epilepsy in the Italy (2016-2027)
  • Figure 19: Prevalence of TSC associated Epilepsy in the Italy (2016-2027)
  • Figure 20: Prevalent Population of Epilepsy in the Spain (2016-2027)
  • Figure 21: Gender specific Prevalent Population of Epilepsy in the Spain (2016-2027)
  • Figure 22: Sub-type specific Prevalent Population of Epilepsy in the Spain (2016-2027)
  • Figure 23: Prevalence of TSC associated Epilepsy in the Spain (2016-2027)
  • Figure 24: Prevalent Population of Epilepsy in the United Kingdom (2016-2027)
  • Figure 25: Gender specific Prevalent Population of Epilepsy in the UK (2016-2027)
  • Figure 26: Sub-type specific Prevalent Population of Epilepsy in the UK (2016-2027)
  • Figure 27: Prevalence of TSC associated Epilepsy in the UK (2016-2027)
  • Figure 28: Prevalent Population of Epilepsy in the Japan (2016-2027)
  • Figure 29: Gender specific Prevalent Population of Epilepsy in the Japan (2016-2027)
  • Figure 30: Sub-type specific Prevalent Population of Epilepsy in the Japan (2016-2027)
Back to Top